Trastuzumab for early breast cancer [6]

Lancet

Volumn 367, Issue 9512, 2006, Pages 728-

  Bryant, John ^a   Geyer, Charles E ^a  

^a NSABP Foundation Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRASTUZUMAB;

BAYES THEOREM; BREAST CARCINOMA; CANCER GRADING; CANCER MORTALITY; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL PROTOCOL; COURSE EVALUATION; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; EARLY CANCER; FOLLOW UP; HAZARD ASSESSMENT; HEART DISEASE; HUMAN; LETTER; MEDICAL ASSESSMENT; PRIORITY JOURNAL; SURVIVAL RATE;

EID: 33644646751     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)68298-6     Document Type: Letter

References (5)

1. The Lancet Herceptin and early breast cancer: a moment for caution Lancet 366 2005 1673
2. EH Romond, EA Perez, J Bryant Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer: combined analysis of NSABP B-31 and NCCTG N9831 N Engl J Med 353 2005 15 26
3. MJ Piccart-Gebhart, M Procter, B Leyland-Jones Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 2005 1659 1672
4. E Tan-Chiu, G Yothers, E Romond Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31 J Clin Oncol 23 2005 7811 7819
5. VM Montori, PJ Devereaux, Adhikari NKJ Randomized trials stopped early for benefit, a systematic review JAMA 294 2005 2203 2209